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Progress Report  
 
Our File No: 34991 
Project Title: REB# 18-093: "Detecting cannabis use with a portable exhaled 
breath device" 
 
The Cannabis Exhaled Breath Analysis study was designed to identify the impact of Cannabis on a person’s 
way of thinking, moving, and responding. D9-Tetrahydrocannabinol (THC) is one of the main compounds 
of cannabis, and responsible for the psychoactive effects. Our study will explore the relationship between 
THC levels in a person’s blood, breath, urine, thinking, moving, and responding over a 5-hour period.   
 
The purpose of this study is to research the feasibility of developing a non-invasive portable breath 
analysis device, the Cannabis Exhaled Breath Analyzer (CEBA), that detects Δ9-Tetrahydrocannabinol 
(THC) 1 at the roadside.  The research was able to identify  semi quantitative results (Low, Med, High) to 
indicate that THC is present in the breath from recent cannabis use, within 1–3 hours of inhalation (Active 
Use).   
 
We aim to isolate a breath signature, called a BreathPrint, that correlates the exhaled THC breath levels 
with the proposed criminal code levels. The limit of < 2 nanograms (ng) per ml (milliliter) will be Low, 
Medium between 2ng-5ng of THC/ml of blood, and High of > 5ng of THC/ml of blood 
 
The participants were recruited via social media from the medical cannabis community in 
Southwestern Ontario, Canada. Three hundred participants signed up for the study, of which 30 
completed a medical interview via a telemedicine service to verify eligibility for the study. 
Twenty-three participants reported to the study, but one withdrew early due to experiencing 
some discomfort after smoking cannabis. Thus, a total of 22 participants completed the full 
design. The study was conducted on a single day, from 8:30 AM to 3:00 PM.  
 
The research protocol included the following steps: 1) Checking in: participants arrived to the 
study site, read and signed the consent form; 2) Nurses conducted a basic health assessment: 
vitals including respiratory rate, heart rate, and blood pressure; 3) First round of cognitive 
testing was performed (“Baseline”); 4) Biosamples (blood, breath, and urine) were collected; 5) 
Cannabis (20% THC) was consumed by participants via vapes, cannabis cigarettes (joints) and 
dabs for 10 minutes and then asked to report their subjective sense of intoxication on a visual 
analogue scale; 6) Participants had 30 minutes of down-time to relax and eat before; 7) Vitals 
and biosamples (blood and breath) were collected again; 8) Second round of cognitive testing 
was performed (“THC”); 9) Down-time with intermittent biosample collection; 10) Final, third 
round of cognitive testing (“Recovery”) was performed; 11) Participants were discharged from 
the study.  
 
In summary, the same brief neuropsychological battery was administered three times to all 
participants: once in the morning, at the beginning of the study (Baseline), once after 
                                                     
 
participants smoked cannabis (THC), and once towards the end of the day (Recovery). 
Psychometric testing was administered by research assistants (RAs) under the supervision of a 
licensed clinical neuropsychologist. RAs received extensive training in test administration and 
scoring, and had previous experience administering these measures in research and clinical 
settings.  The clinical vitals and breath samples were collected by registered nurses, and blood 
was collected by trained phlebotomists. A medical doctor was available for the full duration of 
the study.  
 
